Physician profile
Fen Jiang
NPI 1831312289
$25,130.62
in general payments reported to CMS, 2019-2025
72 companies · $3,197 in 2025
The $3,197 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,706 · 2021: $502 · 2022: $8,587 · 2023: $2,902 · 2024: $4,237 · 2025: $3,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,106 · Long Term Medical Supply Or Device Loan: $1,080 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,106.41 |
| Long Term Medical Supply Or Device Loan | $1,080.33 |
| Education | $148.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $5,473.98 | 2022-2024 | Yescarta |
| Seagen INC. | $4,117.98 | 2019-2023 | Adcetris, Padcev |
| Celgene Corporation | $1,835.99 | 2019-2025 | Opdualag, Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,807.98 | 2022-2025 | |
| Genentech USA, INC. | $1,727.38 | 2022-2025 | Polivy, Itovebi, Lunsumio |
| Exelixis INC. | $1,505.05 | 2021-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $1,034.49 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $796.73 | 2022-2025 | Imfinzi, Calquence, Enhertu |
| Daiichi Sankyo INC. | $534.07 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Incyte Corporation | $527.95 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $305.87 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $282.25 | 2022-2025 | Fruzaqla, Alunbrig, Iclusig |
| Pfizer INC. | $270.90 | 2022-2025 | |
| Janssen Biotech, INC. | $258.13 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Karyopharm Therapeutics INC. | $233.48 | 2023-2025 | Xpovio |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $221.35 | 2022-2025 | Padcev, Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $216.66 | 2022-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $211.44 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Puma Biotechnology, INC. | $200.65 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $198.40 | 2022-2025 | Libtayo |
| Eisai INC. | $179.84 | 2022-2025 | |
| Lilly USA, LLC | $159.96 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Rigel Pharmaceuticals, INC. | $141.58 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $131.84 | 2023-2025 | |
| Blueprint Medicines Corporation | $131.04 | 2023-2025 | Ayvakit |
| Pharmaessentia USA Corporation | $119.37 | 2023-2025 | Besremi |
| Beigene USA, INC. | $112.47 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $112.13 | 2022-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $110.19 | 2023-2025 | Onivyde, Somatuline Depot |
| Amgen INC. | $108.71 | 2022-2025 | Kyprolis, Blincyto, Lumakras |
| Aveo Pharmaceuticals, INC. | $108.65 | 2023-2025 | Fotivda |
| Gilead Sciences, INC. | $107.68 | 2021-2025 | Trodelvy |
| Genmab U.S., INC. | $104.45 | 2023-2025 | Epkinly |
| Taiho Oncology, INC. | $104.08 | 2023-2025 | |
| Array Biopharma INC | $100.85 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Stemline Therapeutics INC. | $98.15 | 2023-2024 | Orserdu |
| Sobi, INC | $95.59 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.20 | 2023-2025 | Gilotrif |
| Coherus Oncology, INC. | $81.95 | 2025 | Loqtorzi, Udenyca |
| Beone Medicines USA, INC. | $75.08 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $71.50 | 2023-2025 | |
| Mirati Therapeutics, INC. | $65.25 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $62.30 | 2022-2024 | |
| Tempus Ai, INC | $58.17 | 2024 | |
| Tersera Therapeutics LLC | $57.32 | 2023-2024 | Quzyttir |
| Emd Serono, INC. | $55.80 | 2023-2025 | Bavencio |
| Agios Pharmaceuticals, INC. | $53.11 | 2023-2024 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $52.73 | 2022-2023 | Qinlock |
| Alnylam Pharmaceuticals INC. | $48.67 | 2023-2025 | Givlaari |
| Iovance Biotherapeutics, INC. | $46.63 | 2025 | Amtagvi |
| Recordati_rare_diseases_inc. | $46.35 | 2025 | Enjaymo, Sylvant |
| Morphosys, US INC. | $39.09 | 2023 | Monjuvi |
| Servier Pharmaceuticals LLC | $38.09 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $33.49 | 2023 | Provenge |
| Sun Pharmaceutical Industries INC. | $31.05 | 2025 | |
| Immunogen, INC. | $29.26 | 2023 | Elahere |
| Chiesi USA, INC. | $28.63 | 2024-2025 | Ferriprox |
| Legend Biotech USA INC. | $24.93 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $24.80 | 2023 | Clonoseq |
| Geron Corporation | $22.50 | 2024 | Rytelo |
| Csl Behring | $21.44 | 2023 | Afstyla, Idelvion |
| Immunocore Limited | $21.00 | 2024 | Kimmtrak |
| Fennec Pharmaceuticals, INC. | $20.24 | 2025 | Fyarro |
| Apellis Pharmaceuticals, INC. | $20.08 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $19.73 | 2023 | Poteligeo |
| Janssen Pharmaceuticals, INC | $17.66 | 2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $17.52 | 2023 | Zepzelca |
| Foundation Medicine, INC. | $17.45 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.80 | 2024 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $16.31 | 2025 | Danziten |
| Syndax Pharmaceuticals, INC. | $16.18 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fen Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.